X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (69) 69
oncology (65) 65
female (62) 62
middle aged (50) 50
adult (45) 45
breast cancer (45) 45
aged (42) 42
breast neoplasms - drug therapy (42) 42
index medicus (33) 33
breast neoplasms - pathology (30) 30
antineoplastic combined chemotherapy protocols - therapeutic use (21) 21
treatment outcome (21) 21
cancer (17) 17
chemotherapy (17) 17
survival (16) 16
metastasis (15) 15
paclitaxel - administration & dosage (14) 14
breast neoplasms - genetics (13) 13
neoplasm metastasis (13) 13
prognosis (13) 13
therapy (13) 13
breast neoplasms - mortality (12) 12
carcinoma (12) 12
trial (12) 12
cyclophosphamide - administration & dosage (11) 11
doxorubicin - administration & dosage (11) 11
fluorouracil - administration & dosage (11) 11
trastuzumab (11) 11
aged, 80 and over (10) 10
antineoplastic combined chemotherapy protocols - administration & dosage (10) 10
article (10) 10
doxorubicin (10) 10
antineoplastic agents, phytogenic - adverse effects (9) 9
cyclophosphamide (9) 9
disease-free survival (9) 9
health aspects (9) 9
immunotherapy (9) 9
paclitaxel (9) 9
paclitaxel - therapeutic use (9) 9
antineoplastic agents, phytogenic - therapeutic use (8) 8
antineoplastic combined chemotherapy protocols - adverse effects (8) 8
breast neoplasms - metabolism (8) 8
metastatic breast cancer (8) 8
neoplasm staging (8) 8
paclitaxel - adverse effects (8) 8
survival analysis (8) 8
toxicity (8) 8
breast neoplasms - surgery (7) 7
care and treatment (7) 7
cells (7) 7
dose-response relationship, drug (7) 7
drug administration schedule (7) 7
prospective studies (7) 7
research (7) 7
time factors (7) 7
tumors (7) 7
vinblastine - analogs & derivatives (7) 7
women (7) 7
adjuvant chemotherapy (6) 6
antigen (6) 6
biomarkers (6) 6
colony-stimulating factor (6) 6
docetaxel (6) 6
male (6) 6
neoadjuvant chemotherapy (6) 6
neoadjuvant therapy (6) 6
predictive value of tests (6) 6
retrospective studies (6) 6
risk factors (6) 6
vinorelbine (6) 6
abridged index medicus (5) 5
antibodies, monoclonal - administration & dosage (5) 5
antineoplastic agents, hormonal - therapeutic use (5) 5
antineoplastic agents, phytogenic - administration & dosage (5) 5
brain metastases (5) 5
breast (5) 5
breast neoplasms - immunology (5) 5
combined modality therapy (5) 5
drug therapy (5) 5
erbb-2 protein (5) 5
expression (5) 5
follow-up studies (5) 5
gene expression profiling (5) 5
gene-expression profiles (5) 5
her2 (5) 5
infusions, intravenous (5) 5
maximum tolerated dose (5) 5
multicenter (5) 5
risk (5) 5
subtypes (5) 5
surgery (5) 5
vinblastine - administration & dosage (5) 5
antineoplastic agents - administration & dosage (4) 4
antineoplastic agents - adverse effects (4) 4
antineoplastic agents - therapeutic use (4) 4
biopsy, needle (4) 4
breast neoplasms - prevention & control (4) 4
breast neoplasms - therapy (4) 4
breast-cancer (4) 4
cancer vaccines - therapeutic use (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Drugs, ISSN 0012-6667, 2006, Volume 66, Issue 7, pp. 949 - 950
Journal Article
International Journal of Cancer, ISSN 0020-7136, 11/2018, Volume 143, Issue 9, pp. 2126 - 2132
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. 1074 - 1074
Journal Article
Nature Communications, ISSN 2041-1723, 06/2017, Volume 8, Issue 1, p. 15916
Deregulation of the cell cycle machinery is a hallmark of cancer. While CDK4/6 inhibitors are FDA approved (palbociclib) for treating advanced estrogen... 
PALBOCICLIB | APOPTOSIS | CELLS | OXIDATIVE STRESS | ADVANCED BREAST-CANCER | MULTIDISCIPLINARY SCIENCES | REGULATES AUTOPHAGY | LETROZOLE | G1 ARREST | DEPENDENT KINASE INHIBITOR | ANTITUMOR-ACTIVITY | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Piperazines - administration & dosage | Cyclin-Dependent Kinase 4 - genetics | Humans | Cellular Senescence - drug effects | Cytoplasm - metabolism | Antineoplastic Agents - administration & dosage | Breast Neoplasms - physiopathology | Cyclin E - genetics | Autophagy - drug effects | Breast Neoplasms - metabolism | Female | Cytoplasm - genetics | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Pyridines - administration & dosage | Retinoblastoma Protein - metabolism | Cyclin-Dependent Kinase 6 - genetics | Cyclin-Dependent Kinase 6 - metabolism | Cyclin-Dependent Kinase 4 - metabolism | Breast Neoplasms - drug therapy | Drug Synergism | Protein Kinase Inhibitors - administration & dosage | Animals | Breast Neoplasms - genetics | Mice, Nude | Retinoblastoma Protein - genetics | Cell Line, Tumor | Mice | Cyclin E - metabolism | Cell Cycle - drug effects | Cytoplasm - drug effects | Senescence | Deregulation | Estrogens | Estrogen | Estrogen receptors | Breast cancer | In vitro testing | Autophagy | Machinery | Cyclin-dependent kinase 4 | Inhibitors | Cell cycle | Xenografts | Biomarkers | Breast | Cyclin E | Bioindicators | Inhibition | Phagocytosis | Tumors | Cancer
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. 1542 - 1542
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 15_suppl, pp. 570 - 570
Journal Article
International Journal of Cancer, ISSN 0020-7136, 11/2018, Volume 143, Issue 9, pp. 2126 - 2132
Journal Article
Journal Article
The Oncologist, ISSN 1083-7159, 05/2017, Volume 22, Issue 5, pp. 526 - 534
摘要 背景 . 本研究旨在按照肿瘤亚型和PET时间评价中期 18 F‐氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(PET/CT)显示的完全代谢缓解(CMR)在接受新辅助化疗(NAC)的乳腺癌(BC)患者中的预后作用。 患者和方法 .... 
Neoadjuvant chemotherapy | Complete metabolic response | Breast cancer | Prognosis | F‐fluorodeoxyglucose positron emission tomography/computed tomography | F-fluorodeoxyglucose positron emission tomography/computed tomography | computed tomography | 18F‐fluorodeoxyglucose positron emission tomography | Breast Cancer
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2010, Volume 28, Issue 28, pp. 4316 - 4323
Journal Article
Cancer, ISSN 0008-543X, 04/2017, Volume 123, Issue 7, pp. 1115 - 1123
Equivocal human epidermal growth factor receptor 2 (HER2) results resemble HER2‐negative cases, not HER2‐amplified cases. Alternative chromosome 17 probes are... 
equivocal human epidermal growth factor receptor 2 (HER2) results | prognostic significance of equivocal human epidermal growth factor receptor 2 (HER2) results | invasive breast cancer | SMS | RARA | alternative chromosome 17 genes in determining human epidermal growth factor receptor 2 (HER2) status | and retinoic acid receptor α | Smith‐Magenis syndrome | genes as alternative chromosome 17 genes | Smith-Magenis syndrome (SMS) and retinoic acid receptor α (RARA) genes as alternative chromosome 17 genes | prognostic significance of equivocal human epidermal | Smith-Magenis syndrome (SMS) and retinoic acid receptor alpha (RARA) genes as alternative chromosome 17 genes | IN-SITU HYBRIDIZATION | 17 COPY NUMBER | CENTROMERE | PATHOLOGICAL COMPLETE RESPONSE | ADJUVANT TRASTUZUMAB | POLYSOMY | AMPLIFICATION | THERAPY | ONCOLOGY | HER2 STATUS | growth factor receptor 2 (HER2) results | AMERICAN-SOCIETY | Immunohistochemistry | Prognosis | Receptor, ErbB-2 - genetics | Humans | Kaplan-Meier Estimate | In Situ Hybridization, Fluorescence | Biomarkers, Tumor | Chromosomes, Human, Pair 17 - genetics | DNA Copy Number Variations | Breast Neoplasms - genetics | Breast Neoplasms - mortality | Female | Breast Neoplasms - diagnosis | Cohort Studies | Usage | Breast cancer | Research | Reflexes | Testing | Enumeration | Copy number | Invasiveness | Genes | Fluorescence | Hazards | Regression analysis | Patients | Survival | ErbB-2 protein | Training | Confidence intervals | Epidermal growth factor | Fluorescence in situ hybridization | Breast | Clinical medicine | Probes | Chromosomes | Retinoic acid | Chromosome 17 | Cancer
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.